1. Home
  2. MIRM vs HUBCW Comparison

MIRM vs HUBCW Comparison

Compare MIRM & HUBCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$80.23

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Logo Hub Cyber Security Ltd. Warrant 2/27/28

HUBCW

Hub Cyber Security Ltd. Warrant 2/27/28

HOLD

Current Price

$0.02

Market Cap

0.0

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
HUBCW
Founded
2018
N/A
Country
United States
Israel
Employees
N/A
322
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
N/A
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
HUBCW
Price
$80.23
$0.02
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$92.45
N/A
AVG Volume (30 Days)
813.7K
N/A
Earning Date
11-04-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$471,794,000.00
N/A
Revenue This Year
$53.78
N/A
Revenue Next Year
$19.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.66
N/A
52 Week Low
$36.88
N/A
52 Week High
$82.58
N/A

Technical Indicators

Market Signals
Indicator
MIRM
HUBCW
Relative Strength Index (RSI) 64.88 44.57
Support Level $63.23 $0.02
Resistance Level $82.58 $0.03
Average True Range (ATR) 3.46 0.01
MACD 1.50 0.00
Stochastic Oscillator 87.13 6.37

Price Performance

Historical Comparison
MIRM
HUBCW

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About HUBCW Hub Cyber Security Ltd. Warrant 2/27/28

Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.

Share on Social Networks: